Insect cell technology is a versatile and robust vaccine manufacturing platform

Expert Review of Vaccines

Volumn 10, Issue 7, 2011, Pages 1063-1081

  Mena, Jimmy A ^a   Kamen, Amine A ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

baculovirus; BEVS; clinical trials; immunogenicity; insect cells; subunit vaccines; vectored vaccines; virus like particles; VLP

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ACID PHOSPHATASE PROSTATE ISOENZYME FUSION PROTEIN; AVIAN INFLUENZA VACCINE; BACULOVIRUS VECTOR; BAYOVAC CSF; CANCER VACCINE; DIAMYD; FLUBLOK; GLUTAMATE DECARBOXYLASE 65; GLYCOPROTEIN D; GLYCOPROTEIN D2; HEPATITIS E VACCINE; HEPATITIS E VIRUS LIKE PARTICLE VACCINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VIRUS LIKE PARTICLE VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS LIKE PARTICLE VACCINE; INGELVAC CIRCOFLEX; JAPANESE ENCEPHALITIS VACCINE; LEISHMANIA VACCINE; MALARIA VACCINE; MEDI-149; MEROZOITE SURFACE PROTEIN 1; NEWCASTLE DISEASE VACCINE; NORWALK; PANBLOK; PORCILIS PESTI; PROVENGE; RECOMBINANT DNA; RECOMBINANT GLUTAMATE DECARBOXYLASE 65; ROTAVIRUS VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VETERINARY DRUG; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE; WEST NILE VACCINE;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; AUTOGRAPHA CALIFORNICA; AUTOGRAPHA CALIFORNICA MULTIPLE NUCLEOPOLYHEDROVIRUS; BACULOVIRUS; BACULOVIRUS EXPRESSION SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INSECT CELL CULTURE; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLYHEDROSIS VIRUS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACULOVIRIDAE; DRUG COMPOUNDING; HUMANS; INSECTS; VACCINATION; VACCINES, SUBUNIT; VACCINES, VIRUS-LIKE PARTICLE;

EID: 80051509160     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.24     Document Type: Review

References (183)

1. Smith GE, Fraser MJ, Summers MD. Molecular engineering of the Autographa californica nuclear polyhedrosis virus genome: deletion mutations within the polyhedrin gene. J. Virol. 46(2), 584-593 (1983). (Pubitemid 13130031)
2. Jarvis DL. Baculovirus-insect cell expression systems. Methods Enzymol. 463, 191-222 (2009).
3. Chung Y-C, Ho M-S, Wu J-C et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26(15), 1855-1862 (2008).
4. Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M. Effcient gene transfer into human hepatocytes by baculovirus vectors. Proc. Natl Acad. Sci. USA 92(22), 10099-10103 (1995).
5. Haynes JR. Infuenza virus-like particle vaccines. Expert Rev. Vaccines 8(4), 435-445 (2009).
6. van Oers MM. Vaccines for viral and parasitic diseases produced with baculovirus vectors. Adv. Virus Res. 68, 193-253 (2006).
7. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA 89(24), 12180-12184 (1992). (Pubitemid 23004809)
8. Wickham TJ, Davis T, Granados RR, Shuler ML, Wood HA. Screening of insect cell lines for the production of recombinant proteins and infectious virus in the baculovirus expression system. Biotechnol. Prog. 8(5), 391-396 (1992). (Pubitemid 23576656)
9. Maranga L, Brazao TF, Carrondo MJT. Virus-like particle production at low multiplicities of infection with the baculovirus insect cell system. Biotechnol. Bioeng. 84(2), 245-253 (2003). (Pubitemid 37176337)
10. Mena JA, Aucoin MG, Montes J, Chahal PS, Kamen AA. Improving adeno-associated vector yield in high density insect cell cultures. J. Gene Med. 12(2), 157-167 (2010).
11. Mena JA, Ramírez OT, Palomares LA. Population kinetics during simultaneous infection of insect cells with two different recombinant baculoviruses for the production of rotavirus-like particles. BMC Biotechnol. 7, 39 (2007).
12. Roldão A, Vieira HLA, Alves PM, Oliveira R, Carrondo MJT. Intracellular dynamics in rotavirus-like particles production: evaluation of multigene and monocistronic infection strategies. Process Biochem. 41(10), 2188-2199 (2006). (Pubitemid 44374386)
13. Maranga L, Rueda P, Antonis A et al. Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl. Microbiol. Biotechnol. 59(1), 45-50 (2002). (Pubitemid 34809674)
14. de Boer M, Conroy L, Min HY, Kwekkeboom J. Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins. J. Immunol. Methods 152(1), 15-23 (1992).
15. Licari P, Bailey JE. Modeling the population dynamics of baculovirus-infected insect cells: optimizing infection strategies for enhanced recombinant protein yields. Biotechnol. Bioeng. 39(4), 432-441 (1992).
16. Yang DG, Chung YC, Lai YK, Lai CW, Liu HJ, Hu YC. Avian infuenza virus hemagglutinin display on baculovirus envelope: cytoplasmic domain affects virus properties and vaccine potential. Mol. Ther. 15(5), 989-996 (2007).
17. Meghrous J, Mahmoud W, Jacob D, Chubet R, Cox M, Kamen AA. Development of a simple and high-yielding fed-batch process for the production of infuenza vaccines. Vaccine 28(2), 309-316 (2009).
18. Redfeld RR, Birx DL, Ketter N et al. A Phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodefciency virus infection. N. Engl. J. Med. 324(24), 1677-1684 (1991).
19. Ludvigsson J, Faresjö M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset Type 1 diabetes. N. Engl. J. Med. 359(18), 1909-1920 (2008).
20. King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin infuenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 27(47), 6589-6594 (2009).
21. Keitel WA, Treanor JJ, El Sahly HM et al. Comparative immunogenicity of recombinant infuenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old. Vaccine 28(2), 379-385 (2009).
22. Cox MMJ, Hollister JR. FluBlok, a next generation infuenza vaccine manufactured in insect cells. Biologicals 37(3), 182-189 (2009).
23. Agardh CD, Lynch KF, Palmér M, Link K, Lernmark Å. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 52(7), 1363-1368 (2009).
24. Mauch L, Seissler J, Haubruck H et al. Baculovirus-mediated expression of human 65 kDa and 67 kDa glutamic acid decarboxylases in SF9 insect cells and their relevance in diagnosis of insulin-dependent diabetes mellitus. J. Biochem. 113(6), 699-704 (1993). (Pubitemid 23201365)
25. Burch PA, Croghan GA, Gastineau DA et al. Immunotherapy (APC8015, provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 60(3), 197-204 (2004) (Pubitemid 38971831)
26. Kan toff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
27. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006). (Pubitemid 46638945)
28. Robinson RA, Burgess WH, Emerson SU et al. Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells. Protein Expr. Purif. 12(1), 75-84 (1998). (Pubitemid 28361972)
29. Purcell RH, Nguyen H, Shapiro M et al. Pre-clinical immunogenicity and effcacy trial of a recombinant hepatitis E vaccine. Vaccine 21(19-20), 2607-2615 (2003). (Pubitemid 36564834)
30. Shrestha MP, Scott RM, Joshi DM et al. Safety and effcacy of a recombinant hepatitis E vaccine. N. Engl. J. Med. 356(9), 895-903 (2007). (Pubitemid 46339908)
31. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 infuenza in humans. Vaccine 19(13-14), 1732-1737 (2001). (Pubitemid 32175735)
32. Wei CJ, Xu L, Kong WP et al. Comparative effcacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 infuenza virus. J. Virol. 82(13), 6200-6208 (2008). (Pubitemid 351875101)
33. Bisht H, Roberts A, Vogel L, Subbarao K, Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 334(2), 160-165 (2005). (Pubitemid 40386951)
34. He Y, Li J, Heck S, Lustigman S, Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J. Virol. 80(12), 5757-5767 (2006). (Pubitemid 43849154)
35. Zhou Z, Post P, Chubet R et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24(17), 3624-3631 (2006).
36. Johansson BE, Brett IC. Recombinant infuenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live infuenza vaccines. Hum. Vaccin. 4(6), 420-424 (2008).
37. Bonafé N, Rininger JA, Chubet RG et al. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells. Vaccine 27(2), 213-222 (2009).
38. Arefan E, Bamdad T, Soleimanjahi H, Akhoond MR, Parsania M, Ghaemi A. A kinetic study of gamma interferon production in herpes simplex virus-1 DNA prime-protein boost regimen comparing to DNA or subunit vaccination. Mol. Biol. 43(3), 388-393 (2009).
39. Fotouhi F, Soleimanjahi H, Roostaee MH, Behzadian F. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting. FEMS Immunol. Med. Microbiol. 54(1), 18-26 (2008).
40. Kimura H, Straus SE, Williams RK. Varicella-zoster virus glycoproteins E and I expressed in insect cells form a heterodimer that requires the N-terminal domain of glycoprotein I. Virology 233(2), 382-391 (1997). (Pubitemid 27314824)
41. Arnot DE, Cavanagh DR, Remarque EJ et al. Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum. Clin. Vaccine Immunol. 15(9), 1345-1355 (2008).
42. Collins WE, Galland GG, Barnwell JW et al. Preliminary observations on the effcacy of a recombinant multistage Plasmodium falciparum vaccine in Aotus nancymai monkeys. Am. J. Trop. Med. Hyg. 73(4), 686-693 (2005). (Pubitemid 41446714)
43. 42 is strain-specifc, antigen and adjuvant dependent, and correlates with antibody responses. PLoS ONE 3(7), e2830 (2008).
44. ® Pesti in pregnant sows. Vet. Microbiol. 77(1-2), 83-97 (2000).
45. Depner KR, Bouma A, Koenen F et al. Classical swine fever (CSF) marker vaccine: trial II. Challenge study in pregnant sows. Vet. Microbiol. 83(2), 107-120 (2001). (Pubitemid 32831477)
46. Dong XN, Chen YH. Marker vaccine strategies and candidate CSFV marker vaccines. Vaccine 25(2), 205-230 (2007).
47. Lipowski A, Drexler C, Pejsak Z. Safety and effcacy of a classical swine fever subunit vaccine in pregnant sows and their offspring. Vet. Microbiol. 77(1-2), 99-108 (2000).
48. Wu CM, Hsuan SL, Chen ZW et al. Expression and immunological studies of classical swine fever virus glycoprotein E2 in the bi-cistronic baculovirus/larvae expression system. Biosci. Biotechnol. Biochem. 74(7), 1343-1349 (2010).
49. Fachinger V, Bischoff R, Jedidia SB, Saalmüller A, Elbers K. The effect of vaccination against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex. Vaccine 26(11), 1488-1499 (2008).
50. Gonzalez DD, Mozgovoj MV, Bellido D et al. Evaluation of a bovine rotavirus VP6 vaccine effcacy in the calf model of infection and disease. Vet. Immunol. Immunopathol. 137(1-2), 155-160 (2010).
51. Thomas C, Young NJ, Heaney J, Collins ME, Brownlie J. Evaluation of effcacy of mammalian and baculovirus expressed E2 subunit vaccine candidates to bovine viral diarrhoea virus. Vaccine 27(17), 2387-2393 (2009).
52. Lee YJ, Sung HW, Choi JG et al. Protection of chickens from Newcastle disease with a recombinant baculovirus subunit vaccine expressing the fusion and hemagglutinin-neuraminidase proteins. J. Vet. Sci. 9(3), 301-308 (2008).
53. Yang DK, Kweon CH, Kim BH et al Immunogenicity of baculovirus expressed recombinant proteins of Japanese encephalitis virus in mice. J. Vet. Sci. 6(2), 125-133 (2005).
54. Lin YJ, Deng MC, Wu SH et al Baculovirus-derived hemagglutinin vaccine protects chickens from lethal homologous virus H5N1 challenge. J. Vet. Med. Sci. 70(11), 1147-1152 (2008).
55. Kaba SA, Musoke AJ, Schaap D et al. Novel baculovirus-derived p67 subunit vaccines effcacious against East Coast fever in cattle. Vaccine 23(21), 2791-2800 (2005). (Pubitemid 40381273)
56. Poot J, Janssen LHM, van Kasteren-Westerneng TJ, van der Heijden-Liefkens KHA, Schijns VEJC, Heckeroth A. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants. Vaccine 27(33), 4439-4446 (2009).
57. Palomares LA, Ramírez OT. Challenges for the production of virus-like particles in insect cells: the case of rotavirus-like particles. Biochemical Engineering Journal 45(3), 158-167 (2009).
58. Aucoin MG, Mena JA, Kamen AA. Bioprocessing of baculovirus vectors: a review. Curr. Gene Ther. 10(3), 174-186 (2010).
59. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. Trichoplusiani cells (High Five™) are highly effcient for the production of infuenza A virus-like particles: a comparison of two insect cell lines as roduction platforms for infuenza vaccines. Mol. Biotechnol. 45(3), 226-234 (2010).
60. Krammer F, Nakowitsch S, Messner P, Palmberger D, Ferko B, Grabherr R. Swine-origin pandemic H1N1 infuenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. Biotechnol. J. 5(1), 17-23 (2010).
61. Deschuyteneer M, Elouahabi A, Plainchamp D et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and-18 cervical cancer vaccine. Hum. Vaccin. 6(5), 407-419 (2010).
62. Marek M, van Oers MM, Devaraj FF, Vlak JM, Merten OW. Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals. Biotechnol Bioeng 108(5), 1056-1067 (2010).
63. Pincus S, Boddapati S, Li J, Sadowski T. Release and stability testing programs for a novel virus-like particle vaccine. BioPharm. Int. 23(10 Suppl.), 26-34 (2010).
64. Peixoto C, Sousa MFQ, Silva AC, Carrondo MJT, Alves PM. Downstream processing of triple layered rotavirus like particles. J. Biotechnol. 127(3), 452-461 (2007). (Pubitemid 44827401)
65. Benavides J, Mena JA, Cisneros-Ruiz M, Ramirez OT, Palomares LA, Rito-Palomares M. Rotavirus-like particles primary recovery from insect cells in aqueous two-phase systems. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 842(1), 48-57 (2006). (Pubitemid 44311089)
66. Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2, 97-105 (2008).
67. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J. Virol. 67(4), 1936-1944 (1993). (Pubitemid 23088366)
68. Bhatla N, Suri V, Basu P et al Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J. Obstet. Gynaecol. Res. 36(1), 123-132 (2010).
69. Paavonen J, Jenkins D, Bosch FX et al. Effcacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369(9580), 2161-2170 (2007). (Pubitemid 46977438)
70. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 5(10), 705-719 (2009).
71. Zhang T, Xu Y, Qiao L et al. Trivalent human papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine 28(19), 3479-3487 (2010).
72. Xu Y, Wang Q, Han Y, Song G, Xu E. Type-specifc and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. J. Med. Microbiol. 56(7), 907-913 (2007). (Pubitemid 47047482)
73. Baek J-O, Seo J-W, Kim I-H, Kim CH. Production and purifcation of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography. Protein Expr. Purif. 75(2), 211-217 (2011).
74. Bansal GP, Hatfeld JA, Dunn FE et al. Candidate recombinant vaccine for human B19 parvovirus. J. Infect. Dis. 167(5), 1034-1044 (1993). (Pubitemid 23115590)
75. Tsao EI, Mason MR, Cacciuttolo MA, Bowen SH, Folena-Wasserman G. Production of parvovirus B19 vaccine in insect cells co-infected with double baculoviruses. Biotechnol. Bioeng. 49(2), 130-138 (1996). (Pubitemid 26011766)
76. Shelly D, Van Cleave V. Parvovirus B19 VLP vaccine manufacturing. Genetic Engineering and Biotechnology News 29(16), 1-3 (2009).
77. Sico C, White S, Tsao E, Varma A. Enhanced kinetic extraction of parvovirus B19 structural proteins. Biotechnol. Bioeng. 80(3), 250-256 (2002). (Pubitemid 35221622)
78. Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J. Infect. Dis. 187(4), 675-678 (2003). (Pubitemid 36250032)
79. Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66(11), 6527-6532 (1992).
80. Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol. 72(2), 1345-1353 (1998). (Pubitemid 28116920)
81. Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. conformational stability and disassembly of norwalk virus-like particles: effect of pH and temperature. J. Biol. Chem. 281(28), 19478-19488 (2006). (Pubitemid 44035452)
82. Nicollier-Jamot B, Ogier A, Piroth L, Pothier P, Kohli E. Recombinant virus-like particles of a norovirus (genogroup II strain) administered intranasally and orally with mucosal adjuvants LT and LT(R192G) in BALB/c mice induce specifc humoral and cellular Th1/Th2-like immune responses. Vaccine 22(9-10), 1079-1086 (2004). (Pubitemid 38296649)
83. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108(3), 241-247 (2003). (Pubitemid 37117370)
84. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum. Vaccin. 4(1), 5-12 (2008). (Pubitemid 351785255)
85. Ward RL, McNeal MM, Steele AD. Why does the world need another rotavirus vaccine? Ther. Clin. Risk Manag. 4(1), 49-63 (2008). (Pubitemid 351460930)
86. Agnello D, Hervé CA, Lavaux A et al. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J. Virol. 80(8), 3823-3832 (2006).
87. Murphy TV, Gargiullo PM, Massoudi MS et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344(8), 564-572 (2001). (Pubitemid 32167870)
88. Mena JA, Ramírez OT, Palomares LA. Intracellular distribution of rotavirus structural proteins and virus-like particles expressed in the insect cell-baculovirus system. J. Biotechnol. 122(4), 443-452 (2006).
89. Madore HP, Estes MK, Zarley CD et al. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine 17(19), 2461-2471 (1999). (Pubitemid 29268370)
90. Kim Y, Chang K-O, Kim W-Y, Saif LJ. Production of hybrid double-or triple-layered virus-like particles of group A and C rotaviruses using a baculovirus expression system. Virology 302(1), 1-8 (2002). (Pubitemid 35356850)
91. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK. Immunogenicity and protective effcacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 21(25-26), 3885-3900 (2003). (Pubitemid 37338216)
92. Shuttleworth G, Eckery DC, Awram P. Oral and intraperitoneal immunization with rotavirus 2/6 virus-like particles stimulates a systemic and mucosal immune response in mice. Arch. Virol. 150(2), 341-349 (2005). (Pubitemid 40177906)
93. Ogier A, Franco MA, Charpilienne A, Cohen J, Pothier P, Kohli E. Distribution and phenotype of murine rotavirus-specifc B cells induced by intranasal immunization with 2/6 virus-like particles. Eur. J. Immunol. 35(7), 2122-2130 (2005). (Pubitemid 41015051)
94. O'Neal CM, Crawford SE, Estes MK, Conner ME. Rotavirus virus-like particles administered mucosally induce protective immunity. J. Virol. 71(11), 8707-8717 (1997). (Pubitemid 27446453)
95. Park JY, Kim H, Hwang HK et al. Large-scale production of rotavirus VLP as vaccine candidate using baculovirus expression vector system (BEVS). J. Microbiol. Biotechnol. 14(1), 35-40 (2004). (Pubitemid 38325054)
96. Parez N, Fourgeux C, Mohamed A et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J. Virol. 80(4), 1752-1761 (2006). (Pubitemid 43228716)
97. Ciarlet M, Crawford SE, Barone C et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J. Virol. 72(11), 9233-9246 (1998). (Pubitemid 28471870)
98. Istrate C, Hinkula J, Charpilienne A et al. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine 26(35), 4594-4601 (2008).
99. Palomares LA, López S, Ramírez OT. Strategies for manipulating the relative concentration of recombinant rotavirus structural proteins during simultaneous production by insect cells. Biotechnol. Bioeng. 78(6), 635-644 (2002). (Pubitemid 34712349)
100. Vieira HLA, Estêvão C, Roldão A et al. Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production. J. Biotechnol. 120(1), 72-82 (2005). (Pubitemid 41384152)
101. Li TC, Suzaki Y, Ami Y, Dhole TN, Miyamura T, Takeda N. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine 22(3-4), 370-377 (2004). (Pubitemid 37510267)
102. Chung C-Y, Chen C-Y, Lin S-Y et al. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 28(43), 6951-6957 (2010).
103. Goldmann C, Petry H, Frye S et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J. Virol. 73(5), 4465-4469 (1999). (Pubitemid 29189897)
104. Chung YC, Huang JH, Lai CW et al. Expression, purifcation and characterization of enterovirus-71 virus-like particles. World J. Gastroenterol. 12(6), 921-927 (2006).
105. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Infuenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 infuenza virus induce protective immune responses in BALB/c mice. Vaccine 23(50), 5751-5759 (2005). (Pubitemid 41668881)
106. Matassov D, Cupo A, Galarza JM. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 infuenza A virus (H1N1). Viral Immunol. 20(3), 441-452 (2007). (Pubitemid 47585318)
107. Bright RA, Carter DM, Daniluk S et al. Infuenza virus-like particles elicit broader immune responses than whole virion inactivated infuenza virus or recombinant hemagglutinin. Vaccine 25(19), 3871-3878 (2007). (Pubitemid 46589748)
108. Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to infuenza viruses with H5N1 HA and NA elicited by an infuenza virus-like particle. PLoS ONE 3(1), e1501 (2008).
109. Mahmood K, Bright RA, Mytle N et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 infuenza viruses. Vaccine 26(42), 5393-5399 (2008).
110. Kang SM, Yoo DG, Lipatov AS et al. Induction of long-term protective immune responses by infuenza H5N1 virus-like particles. PLoS ONE 4(3), e4667 (2009).
111. Pushko P, Kort T, Nathan M, Pearce MB, Smith G, Tumpey TM. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 infuenza virus. Vaccine 28(30), 4771-4776 (2010).
112. Galarza JM, Latham T, Cupo A. Virus-like particle vaccine conferred complete protection against a lethal infuenza virus challenge. Viral Immunol. 18(2), 365-372 (2005). (Pubitemid 41106015)
113. Krammer F, Schinko T, Messner P, Palmberger D, Ferko B, Grabherr R. Infuenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis. J. Virol. Methods 167(1), 17-22 (2010).
114. Lu X, Chen Y, Bai B et al. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology 122(4), 496-502 (2007). (Pubitemid 350075956)
115. Ho Y, Lin PH, Liu CYY, Lee SP, Chao YC. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem. Biophys. Res. Commun. 318(4), 833-838 (2004). (Pubitemid 38625848)
116. Bai B, Hu Q, Hu H et al. Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PLoS ONE 3(7), e2685 (2008).
117. Lu B, Huang Y, Huang L et al. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. Immunology 130(2), 254-261 (2010).
118. Ye L, Lin J, Sun Y et al. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 351(2), 260-270 (2006). (Pubitemid 44108063)
119. Sun Y, Carrion R Jr, Ye L et al. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 383(1), 12-21 (2009).
120. Warfeld KL, Posten NA, Swenson DL et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J. Infect. Dis. 196(Suppl. 2), S421-S429 (2007). (Pubitemid 351417290)
121. Yang C, Ye L, Compans RW. Protection against flovirus infection: virus-like particle vaccines. Expert Rev. Vaccines 7(3), 333-344 (2008). (Pubitemid 351520021)
122. Fort M, Sibila M, Allepuz A, Mateu E, Roerink F, Segalés J. Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins. Vaccine 26(8), 1063-1071 (2008).
123. Fort M, Sibila M, Pérez-Martín E, Nofrarías M, Mateu E, Segalés J. One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and signifcantly reduces PCV2 viremia in an experimental model. Vaccine 27(30), 4031-4037 (2009).
124. Fan H, Ju C, Tong T, Huang H, Lv J, Chen H. Immunogenicity of empty capsids of porcine circovius type 2 produced in insect cells. Vet. Res. Commun. 31(4), 487-496 (2007).
125. Liu LJ, Suzuki T, Tsunemitsu H et al. Effcient production of type 2 porcine circovirus-like particles by a recombinant baculovirus. Arch. Virol. 153(12), 2291-2295 (2008).
126. Pérez-Martín E, Gómez-Sebastián S, Argilaguet JM et al. Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae. Vaccine 28(11), 2340-2349 (2010).
127. Antonis AFG, Bruschke CJM, Rueda P et al. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 24(26), 5481-5490 (2006). (Pubitemid 43831379)
128. Stewart M, Bhatia Y, Athmaran TN et al. Validation of a novel approach for the rapid production of immunogenic virus-like particles for Bluetongue virus. Vaccine 28(17), 3047-3054 (2010).
129. Prel A, Le Gall-Reculé G, Cherbonnel M, Grasland B, Amelot M, Jestin V. Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian infuenza virus challenge in Muscovy ducks. Avian Dis. 51(Suppl. 1), 484-489 (2007). (Pubitemid 46671339)
130. Prel A, Le Gall-Reculé G, Jestin V. Achievement of avian infuenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian infuenza strains in ducks. Avian Pathol. 37(5), 513-520 (2008).
131. Cao Y, Lu Z, Sun J et al. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs. Vet. Microbiol. 137(1-2), 10-17 (2009).
132. Martínez C, Dalsgaard K, López de Turiso J, Cortés E, Vela C, Casal J. Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine 10(10), 684-690 (1992).
133. Madhan S, Prabakaran M, Kwang J. Baculovirus as vaccine vectors Curr. Gene Ther. 10(3), 201-213 (2010).
134. Hu YC, Yao K, Wu TY Baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Rev. Vaccines 7(3), 363-371 (2008). (Pubitemid 351520024)
135. He F, Madhan S, Kwang J. Baculovirus vector as a delivery vehicle for infuenza vaccines. Expert Rev. Vaccines 8(4), 455-467 (2009).
136. Barsoum J, Brown R, McKee M, Boyce FM. Effcient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein. Hum. Gene Ther. 8(17), 2011-2018 (1997).
137. Wang S, Fang L, Fan H et al. Construction and immunogenicity of pseudotype baculovirus expressing GP5 and M protein of porcine reproductive and respiratory syndrome virus. Vaccine 25 (49), 8220-8227 (2007). (Pubitemid 350087390)
138. Vicente T, Peixoto C, Carrondo MJT, Alves PM. Purifcation of recombinant baculoviruses for gene therapy using membrane processes. Gene Ther. 16(6), 766-775 (2009).
139. Hu YC, Tsai CT, Chung YC, Lu JT, Hsu JTA. Generation of chimeric baculovirus with histidine-tags displayed on the envelope and its purifcation using immobilized metal affnity chromatography Enzyme Microb. Technol. 33(4), 445-452 (2003).
140. Transfguracion J, Jorio H, Meghrous J, Jacob D, Kamen A. High yield purifcation of functional baculovirus vectors by size exclusion chromatography. J. Virol. Methods 142(1-2), 21-28 (2007). (Pubitemid 46590402)
141. Wu C, Ker YS, Wang S. Ion-exchange membrane chromatography method for rapid and effcient purifcation of recombinant baculovirus and baculovirus gp64 protein. Hum. Gene Ther. 18(7), 665-672 (2007). (Pubitemid 47187097)
142. Chen CY, Liu HJ, Tsai CP et al. Baculovirus as an avian infuenza vaccine vector: differential immune responses elicited by different vector forms. Vaccine 28(48), 7644-7651 (2010).
143. Yoshida S, Kawasaki M, Hariguchi N, Hirota K, Matsumoto M. A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infect. Immun. 77(5), 1782-1789 (2009).
144. Strauss R, Hüser A, Ni S et al. Baculovirus-based vaccination vectors allow for effcient induction of immune responses against Plasmodium falciparum circumsporozoite protein. Mol. Ther. 15(1), 193-202 (2007). (Pubitemid 46043665)
145. Jin R, Lv Z, Chen Q et al. Safety and Immunogenicity of H5N1 infuenza vaccine based on baculovirus surface display system of Bombyx mori. PLoS ONE 3(12), e3933 (2008).
146. Peakman M, Tree TI, Endl J, Van Endert P, Atkinson MA, Roep BO. Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-Cells in Type 1 Diabetes: report of Phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell Assays in Type 1 Diabetes. Diabetes 50(8), 1749-1754 (2001). (Pubitemid 33641592)
147. Burch PA, Breen JK, Buckner JC et al. Priming tissue-specifc cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6(6), 2175-2182 (2000). (Pubitemid 30399182)
148. Dosch SF, Mahajan SD, Collins AR. SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kB pathway in human monocyte macrophages in vitro. Virus Res. 142(1-2), 19-27 (2009).
149. Meeusen ENT, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. Clin. Microbiol. Rev. 20(3), 489-510 (2007). (Pubitemid 47175016)
150. Bouma A, De Smit AJ, De Kluijver EP, Terpstra C, Moormann RJM. Effcacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus. Vet. Microbiol. 66(2), 101-114 (1999). (Pubitemid 29131479)
151. Kixmöller M, Ritzmann M, Eddicks M, Saalmüller A, Elbers K, Fachinger V. Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2. Vaccine 26(27-28), 3443-3451 (2008).
152. Opriessnig T, Patterson AR, Madson DM, Pal N, Halbur PG. Comparison of effcacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV-PCV2-SIV clinical infection model 2-3-months post vaccination. Vaccine 27(7), 1002-1007 (2009).
153. Senger T, Schädlich L, Gissmann L, Müller M. Enhanced papillomavirus-like particle production in insect cells. Virology 388(2), 344-353 (2009).
154. Franssila R, Hedman K. T-helper cell-mediated interferon-g, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19. Vaccine 22(27-28), 3809-3815 (2004). (Pubitemid 39099658)
155. Kissmann J, Ausar SF, Foubert TR et al. Physical stabilization of norwalk virus-like particles. J. Pharma. Sci. 97(10), 4208-4218 (2008).
156. El-Attar L, Oliver SL, Mackie A et al. Comparison of the effcacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease. Vaccine 27(24), 3201-3208 (2009).
157. Azevedo MSP, Gonzalez AM, Yuan L et al. An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes infuences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model. Clin. Vaccine Immunol. 17(3), 420-428 (2010).
158. Wen Z, Ye L, Gao Y et al. Immunization by infuenza virus-like particles protects aged mice against lethal infuenza virus challenge. Antiviral Res. 84(3), 215-224 (2009).
159. Haynes JR, Dokken L, Wiley JA et al. Infuenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian infuenza challenge. Vaccine 27(4), 530-541 (2009).
160. Buonaguro L, Tornesello ML, Tagliamonte M et al. Baculovirus-derived human immunodefciency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J. Virol. 80(18), 9134-9143 (2006). (Pubitemid 44362963)
161. Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodefciency virus type 1 clade A virus-like particles administered by different routes of inoculation. J. Virol. 79(11), 7059-7067 (2005). (Pubitemid 40677337)
162. gag virus-like particle vaccine effciently boosts baboons primed with a matched DNA vaccine. J. Gen. Virol. 89(9), 2214-2227 (2008).
163. gag virus-like particles are potent activators of human monocytes. Virology 382(1), 46-58 (2008).
164. Bai B, Lu X, Meng J et al. Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses. Mol. Immunol. 45(4), 868-875 (2008). (Pubitemid 350016349)
165. Qiao M, Ashok M, Bernard KA et al. Induction of sterilizing immunity against West Nile virus (WNV), by immunization with WNV-like particles produced in insect cells. J. Infect. Dis. 190(12), 2104-2108 (2004). (Pubitemid 39636357)
166. Li Z, Yi Y, Yin X, Zhang Z, Liu J. Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine. PLoS ONE 3(5), e2273 (2008).
167. Prabakaran M, He F, Meng T et al. Neutralizing epitopes of infuenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J. Virol. 84(22), 11822-11830 (2010).
168. Prabakaran M, Madhan S, Prabhu N, Geng GY, New R, Kwang J. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antiviral Res. 86(2), 180-187 (2010).
169. Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J. Gastrointestinal delivery of baculovirus displaying infuenza virus hemagglutinin protects mice against heterologous H5N1 infection. J. Virol. 84(7), 3201-3209 (2010).
170. Tang X-C, Lu H-R, Ross TM. Hemagglutinin displayed baculovirus protects against highly pathogenic infuenza. Vaccine 28(42), 6821-6831 (2010).
171. Mlambo G, Kumar N, Yoshida S. Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen. Vaccine 28(43), 7025-7029 (2010).
172. Yoshida S, Araki H, Yokomine T. Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. Infect. Immun. 78(2), 595-602 (2010).
173. Feng Q, Liu Y, Qu X et al. Baculovirus surface display of SARS coronavirus (SARS-CoV) spike protein and immunogenicity of the displayed protein in mice models. DNA Cell Biol. 25(12), 668-673 (2006). (Pubitemid 46052612)
174. Peralta A, Molinari P, Conte-Grand D, Calamante G, Taboga O. A chimeric baculovirus displaying bovine herpesvirus-1 (BHV-1) glycoprotein D on its surface and their immunological properties. Appl. Microbiol. Biotechnol. 75(2), 407-414 (2007). (Pubitemid 46866531)
175. Fang R, Feng H, Nie H et al. Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice model. Vaccine 28(7), 1803-1807 (2010).
176. Li Y, Ye J, Cao S et al. Immunization with pseudotype baculovirus expressing envelope protein of Japanese encephalitis virus elicits protective immunity in mice. J. Gene Med. 11(1), 57-65 (2009).
177. Molinari P, Bianco V, Peralta A et al. Recombinant baculoviruses as vehicles for presentation and adjuvancy of antigens for the development of new tuberculosis candidate vaccines. Procedia in Vaccinology 1(1), 81-84 (2009).
178. Li M, Wang YF, Wang Y et al. Immune responses induced by a BacMam virus expressing the E2 protein of classical swine fever virus in mice. Immunol. Lett. 125(2), 145-150 (2009).
179. Xu X-G, Chiou M-T, Zhang Y-M et al. Baculovirus surface display of Erns envelope glycoprotein of classical swine fever virus. J. Virol. Methods 153(2), 149-155 (2008).
180. Xu X-G, Tong D-W, Chiou M-T et al. Baculovirus surface display of NS3 nonstructural protein of classical swine fever virus. J. Virol. Methods 159(2), 259-264 (2009).
181. Wu Q, Fang L, Wu X et al. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian infuenza virus in mice and chickens. Mol. Immunol. 46(11-12), 2210-2217 (2009).
182. Grabowska AK, Lipinska AD, Rohde J, Szewczyk B, Bienkowska-Szewczyk K, Rziha H-J. New baculovirus recombinants expressing Pseudorabies virus (PRV) glycoproteins protect mice against lethal challenge infection. Vaccine 27(27), 3584-3591 (2009).
183. Fan H, Pan Y, Fang L et al. Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice. J. Virol. Methods 150(1-2), 21-26 (2008).